We have found that sarcoma tumors with combined high levels of CDK4 mRNA and low levels of p16INK4a, respond to palbociclib (a CDK4 inhibitor) in a panel of PDX models in vivo, irrespective of the tumor type [11]. Here, CDK4 is linked to sarcoma.